AngioDynamics (NASDAQ:ANGO) Given Buy Rating at Canaccord Genuity Group

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $20.00 price objective on the medical instruments supplier’s stock. Canaccord Genuity Group’s price objective suggests a potential upside of 73.61% from the company’s current price.

Several other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright boosted their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Finally, Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Trading Up 2.6%

ANGO stock traded up $0.29 during midday trading on Friday, reaching $11.52. The company had a trading volume of 2,156,060 shares, compared to its average volume of 506,590. The company has a 50 day moving average of $15.39 and a two-hundred day moving average of $13.11. The company has a market capitalization of $484.42 million, a P/E ratio of -13.24 and a beta of 0.30. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts anticipate that AngioDynamics will post -0.25 earnings per share for the current year.

Insider Activity

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANGO. Integrated Wealth Concepts LLC acquired a new stake in AngioDynamics during the 2nd quarter worth $38,000. Corient Private Wealth LP acquired a new stake in AngioDynamics during the 2nd quarter worth $134,000. Public Employees Retirement System of Ohio acquired a new position in shares of AngioDynamics during the 2nd quarter worth about $64,000. Bank of America Corp DE acquired a new position in shares of AngioDynamics during the 2nd quarter worth about $4,490,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new position in shares of AngioDynamics during the 2nd quarter worth about $589,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.